drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB01261 | DB01319 | 170 | 34 | [
"DDInter1679",
"DDInter777"
] | Sitagliptin | Fosamprenavir | Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus[FDA label,A2260,A2255,A2256]. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improv... | Fosamprenavir is a prodrug of amprenavir, an inhibitor of human immunodeficiency virus (HIV) protease. | Moderate | 1 | [
[
[
170,
24,
34
]
],
[
[
170,
63,
1091
],
[
1091,
40,
34
]
],
[
[
170,
6,
8374
],
[
8374,
45,
34
]
],
[
[
170,
21,
28723
],
[
28723,
... | [
[
[
"Sitagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosamprenavir"
]
],
[
[
"Sitagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amprenavir"
],
... | Sitagliptin may cause a moderate interaction that could exacerbate diseases when taken with Amprenavir and Amprenavir (Compound) resembles Fosamprenavir (Compound)
Sitagliptin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Fosamprenavir (Compound)
Sitagliptin (Compound) causes Malnutrition (Side Effect) a... |
DB00938 | DB01210 | 455 | 668 | [
"DDInter1635",
"DDInter1050"
] | Salmeterol | Levobunolol (ophthalmic) | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salm... | Levobunolol is a cyclic ketone that is 3,4-dihydronaphthalen-1-one substituted at position 5 by a 3-(tert-butylamino)-2-hydroxypropoxy group (the S-enantiomer). A non-selective beta-adrenergic antagonist used (as its hydrochloride salt) for treatment of glaucoma. It has a role as an antiglaucoma drug and a beta-adrener... | Major | 2 | [
[
[
455,
25,
668
]
],
[
[
455,
64,
461
],
[
461,
1,
668
]
],
[
[
455,
24,
688
],
[
688,
25,
668
]
],
[
[
455,
25,
887
],
[
887,
1,
... | [
[
[
"Salmeterol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Levobunolol"
]
],
[
[
"Salmeterol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Timolol"
],
[
"Timolol",
"{u} (Compo... | Salmeterol may lead to a major life threatening interaction when taken with Levobunolol
Salmeterol may lead to a major life threatening interaction when taken with Timolol and Timolol (Compound) resembles Levobunolol (Compound)
Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with S... |
DB00390 | DB11158 | 1,252 | 1,452 | [
"DDInter554",
"DDInter1401"
] | Digoxin | Pectin | Digoxin is one of the oldest cardiovascular medications used today. It is a common agent used to manage atrial fibrillation and the symptoms of heart failure. Digoxin is classified as a cardiac glycoside and was initially approved by the FDA in 1954. This drug originates from the foxglove plant, also known as the _Digi... | Pectin is a heteropolysaccharide commercially derived from the cell wall of higher plants. It is composed of partially methylated polygalacturonic acid units linked in the positions 1-4. The carboxylic group of the constituents of pectin can exist in the form of esters, free acids, ammonium, potassium or sodium salts o... | Moderate | 1 | [
[
[
1252,
24,
1452
]
],
[
[
1252,
1,
1482
],
[
1482,
24,
1452
]
],
[
[
1252,
10,
11576
],
[
11576,
44,
681
],
[
681,
24,
1452
]
],
[
[
125... | [
[
[
"Digoxin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pectin"
]
],
[
[
"Digoxin",
"{u} (Compound) resembles {v} (Compound)",
"Digitoxin"
],
[
"Digitoxin",
"{u} may cause a moderate interactio... | Digoxin (Compound) resembles Digitoxin (Compound) and Digitoxin may cause a moderate interaction that could exacerbate diseases when taken with Pectin
Digoxin (Compound) palliates coronary artery disease (Disease) and coronary artery disease (Disease) is treated by Pravastatin (Compound) and Pravastatin may cause a mod... |
DB00196 | DB01246 | 600 | 820 | [
"DDInter743",
"DDInter45"
] | Fluconazole | Alimemazine | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole ... | A phenothiazine derivative that is used as an antipruritic. | Moderate | 1 | [
[
[
600,
24,
820
]
],
[
[
600,
24,
401
],
[
401,
24,
820
]
],
[
[
600,
24,
675
],
[
675,
25,
820
]
],
[
[
600,
24,
508
],
[
508,
1,
... | [
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
]
],
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
... | Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Dextropropoxyp... |
DB06779 | DB15035 | 365 | 503 | [
"DDInter470",
"DDInter1959"
] | Dalteparin | Zanubrutinib | Dalteparin, a low molecular weight heparin (LMWH) prepared by nitrous acid degradation of unfractionated heparin of porcine intestinal mucosa origin, is an anticoagulant. It is composed of strongly acidic sulphated polysaccharide chains with an average molecular weight of 5000 and about 90% of the material within the r... | Zanubrutinib is a novel Bruton's tyrosine kinase (BTK) inhibitor used for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Mantle cell lymphoma is an aggressive mature B-cell non-Hodgkin lymphoma associated with early relapse, poor clinical outcomes, and long... | Major | 2 | [
[
[
365,
25,
503
]
],
[
[
365,
63,
222
],
[
222,
24,
503
]
],
[
[
365,
24,
738
],
[
738,
24,
503
]
],
[
[
365,
64,
39
],
[
39,
25,
... | [
[
[
"Dalteparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zanubrutinib"
]
],
[
[
"Dalteparin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutra... | Dalteparin may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Zanubrutinib
Dalteparin may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Nir... |
DB00637 | DB01035 | 1,557 | 1,401 | [
"DDInter128",
"DDInter1524"
] | Astemizole | Procainamide | Astemizole is a long-acting, non-sedating second generation antihistamine used in the treatment of allergy symptoms. It was withdrawn from market by the manufacturer in 1999 due to the potential to cause arrhythmias at high doses, especially when when taken with CYP inhibitors or grapefruit juice. | A derivative of procaine with less CNS action. | Major | 2 | [
[
[
1557,
25,
1401
]
],
[
[
1557,
6,
12523
],
[
12523,
45,
1401
]
],
[
[
1557,
23,
112
],
[
112,
23,
1401
]
],
[
[
1557,
24,
770
],
[
770,... | [
[
[
"Astemizole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Procainamide"
]
],
[
[
"Astemizole",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Proca... | Astemizole (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Procainamide (Compound)
Astemizole may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Procainamide
Astemizole m... |
DB01129 | DB09263 | 379 | 1,436 | [
"DDInter1559",
"DDInter1399"
] | Rabeprazole | Patiromer | Rabeprazole is an antiulcer drug in the class of proton pump inhibitors. It is a prodrug - in the acid environment of the parietal cells it turns into active sulphenamide form. Rabeprazole inhibits the H+, K+ATPase of the coating gastric cells and dose-dependent oppresses basal and stimulated gastric acid secretion. | Patiromer is a powder for suspension in water for oral administration, approved in the U.S. as Veltassa in October, 2015. Patiromer is supplied as patiromer sorbitex calcium which consists of the active moiety, patiromer, a non-absorbed potassium-binding polymer, and a calcium-sorbitol counterion. Each gram of patirome... | Moderate | 1 | [
[
[
379,
24,
1436
]
],
[
[
379,
40,
660
],
[
660,
24,
1436
]
],
[
[
379,
24,
428
],
[
428,
63,
1436
]
],
[
[
379,
63,
1152
],
[
1152,
... | [
[
[
"Rabeprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Patiromer"
]
],
[
[
"Rabeprazole",
"{u} (Compound) resembles {v} (Compound)",
"Esomeprazole"
],
[
"Esomeprazole",
"{u} may cause a mo... | Rabeprazole (Compound) resembles Esomeprazole (Compound) and Esomeprazole may cause a moderate interaction that could exacerbate diseases when taken with Patiromer
Rabeprazole may cause a moderate interaction that could exacerbate diseases when taken with Ferrous fumarate and Ferrous fumarate may cause a moderate inter... |
DB00370 | DB00526 | 1,251 | 1,555 | [
"DDInter1230",
"DDInter1355"
] | Mirtazapine | Oxaliplatin | Mirtazapine is a tetracyclic _piperazino-azepine_ antidepressant agent that was initially approved for the treatment of major depressive disorder (MDD) in the Netherlands in 1994. This drug was first manufactured by Organon Inc., and received FDA approval in 1997 for the treatment of major depressive disorder.[T595, L6... | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of t... | Moderate | 1 | [
[
[
1251,
24,
1555
]
],
[
[
1251,
6,
7950
],
[
7950,
45,
1555
]
],
[
[
1251,
24,
79
],
[
79,
24,
1555
]
],
[
[
1251,
24,
1213
],
[
1213,
... | [
[
[
"Mirtazapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
]
],
[
[
"Mirtazapine",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound... | Mirtazapine (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Oxaliplatin (Compound)
Mirtazapine may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin
Mirtazapine may ... |
DB00245 | DB01142 | 357 | 1,264 | [
"DDInter181",
"DDInter593"
] | Benzatropine | Doxepin | Benztropine, with the chemical formula 3alpha-diphenylmethoxytropane, is a tropane-based dopamine inhibitor used for the symptomatic treatment of Parkinson's disease. It is a combination molecule between a tropane ring, similar to cocaine, and a diphenyl ether from the dialkylpiperazines determined to be a dopamine upt... | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Moderate | 1 | [
[
[
357,
24,
1264
]
],
[
[
357,
24,
401
],
[
401,
24,
1264
]
],
[
[
357,
24,
649
],
[
649,
63,
1264
]
],
[
[
357,
6,
4304
],
[
4304,
... | [
[
[
"Benzatropine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Benzatropine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[... | Benzatropine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Benzatropine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and C... |
DB00224 | DB08899 | 215 | 129 | [
"DDInter917",
"DDInter649"
] | Indinavir | Enzalutamide | A potent and specific HIV protease inhibitor that appears to have good oral bioavailability. [PubChem] | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Moderate | 1 | [
[
[
215,
24,
129
]
],
[
[
215,
6,
8374
],
[
8374,
45,
129
]
],
[
[
215,
21,
29377
],
[
29377,
60,
129
]
],
[
[
215,
24,
608
],
[
608,
... | [
[
[
"Indinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Indinavir",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",... | Indinavir (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Enzalutamide (Compound)
Indinavir (Compound) causes Musculoskeletal pain (Side Effect) and Musculoskeletal pain (Side Effect) is caused by Enzalutamide (Compound)
Indinavir may cause a moderate interaction that could exacerbate diseases when taken w... |
DB00087 | DB06643 | 599 | 1,136 | [
"DDInter41",
"DDInter500"
] | Alemtuzumab | Denosumab | Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52. The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant region... | Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption via inhibiting RANK-mediated activation of osteoclasts. It is the first and currently the only RANKL inhibitor approved to prevent osteoclast-mediated bone loss.... | Moderate | 1 | [
[
[
599,
24,
1136
]
],
[
[
599,
24,
1213
],
[
1213,
24,
1136
]
],
[
[
599,
24,
1316
],
[
1316,
63,
1136
]
],
[
[
599,
63,
1648
],
[
1648,
... | [
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Denosumab"
]
],
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
],
[
... | Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Denosumab
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Durvalumab and Durvalu... |
DB00906 | DB01259 | 1,567 | 392 | [
"DDInter1801",
"DDInter1024"
] | Tiagabine | Lapatinib | Tiagabine is an anti-convulsive medication. It is also used in the treatment for panic disorder as are a few other anticonvulsants. Though the exact mechanism by which tiagabine exerts its effect on the human body is unknown, it does appear to operate as a selective GABA reuptake inhibitor. | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Moderate | 1 | [
[
[
1567,
24,
392
]
],
[
[
1567,
6,
8374
],
[
8374,
45,
392
]
],
[
[
1567,
21,
28688
],
[
28688,
60,
392
]
],
[
[
1567,
63,
1010
],
[
1010... | [
[
[
"Tiagabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
]
],
[
[
"Tiagabine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Tiagabine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Lapatinib (Compound)
Tiagabine (Compound) causes Epistaxis (Side Effect) and Epistaxis (Side Effect) is caused by Lapatinib (Compound)
Tiagabine may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine and Mefloquin... |
DB08899 | DB12457 | 129 | 1,180 | [
"DDInter649",
"DDInter1598"
] | Enzalutamide | Rimegepant | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Rimegepant is an oral antagonist of the CGRP receptor developed by Biohaven Pharmaceuticals. It received FDA approval on February 27, 2020 for the acute treatment migraine headache, and was subsequently approved by the European Commission in April 2022 for both the treatment and prevention of migraines. While several p... | Major | 2 | [
[
[
129,
25,
1180
]
],
[
[
129,
25,
741
],
[
741,
24,
1180
]
],
[
[
129,
24,
1619
],
[
1619,
24,
1180
]
],
[
[
129,
64,
1419
],
[
1419,
... | [
[
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rimegepant"
]
],
[
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rolapitant"
],
[
"Rolapitant",
"{... | Enzalutamide may lead to a major life threatening interaction when taken with Rolapitant and Rolapitant may cause a moderate interaction that could exacerbate diseases when taken with Rimegepant
Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may caus... |
DB00215 | DB00835 | 1,230 | 100 | [
"DDInter388",
"DDInter245"
] | Citalopram | Brompheniramine | Citalopram is an antidepressant belonging to the class of selective _serotonin-reuptake inhibitors_ (SSRIs) widely used to treat the symptoms of depression. It is a racemic bicyclic phthalate derivate and is the only compound with a tertiary amine and 2 nitrogen-containing metabolites among all SSRIs.[A261316,A14720] C... | Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria. | Moderate | 1 | [
[
[
1230,
24,
100
]
],
[
[
1230,
24,
832
],
[
832,
24,
100
]
],
[
[
1230,
24,
28
],
[
28,
40,
100
]
],
[
[
1230,
24,
649
],
[
649,
6... | [
[
[
"Citalopram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
]
],
[
[
"Citalopram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
],... | Citalopram may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine and Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine
Citalopram may cause a moderate interaction that could exacerbate diseases when taken with Bisacody... |
DB00816 | DB09043 | 1,674 | 135 | [
"DDInter1346",
"DDInter36"
] | Orciprenaline | Albiglutide | A beta-adrenergic agonist used in the treatment of asthma and bronchospasms. [PubChem] | Albiglutide is a glucagon-like peptide-1 agonist (GLP-1) biologic drug indicated in the treatment of type 2 diabetes. It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline). It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. Albiglutide was approved on A... | Moderate | 1 | [
[
[
1674,
24,
135
]
],
[
[
1674,
63,
1647
],
[
1647,
23,
135
]
],
[
[
1674,
24,
519
],
[
519,
24,
135
]
],
[
[
1674,
63,
323
],
[
323,
... | [
[
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Albiglutide"
]
],
[
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acarbose"
],
... | Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Acarbose and Acarbose may cause a minor interaction that can limit clinical effects when taken with Albiglutide
Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Paliperidone and Pal... |
DB00006 | DB00374 | 942 | 1,061 | [
"DDInter217",
"DDInter1852"
] | Bivalirudin | Treprostinil | Bivalirudin is a synthetic 20 residue peptide (thrombin inhibitor) which reversibly inhibits thrombin. Once bound to the active site, thrombin cannot activate fibrinogen into fibrin, the crucial step in the formation of thrombus. It is administered intravenously. Because it can cause blood stagnation, it is important t... | Treprostinil is a stable tricyclic analogue of prostacyclin that promotes the vasodilation of pulmonary and systemic arterial vascular beds and the inhibition of platelet aggregation.[L41855,L41860,L41865] It reduces symptoms in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated w... | Moderate | 1 | [
[
[
942,
24,
1061
]
],
[
[
942,
24,
885
],
[
885,
40,
1061
]
],
[
[
942,
23,
539
],
[
539,
62,
1061
]
],
[
[
942,
25,
582
],
[
582,
... | [
[
[
"Bivalirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
]
],
[
[
"Bivalirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
],
... | Bivalirudin may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol (Compound) resembles Treprostinil (Compound)
Bivalirudin may cause a minor interaction that can limit clinical effects when taken with Capsicum and Capsicum may cause a minor interaction that can li... |
DB00322 | DB04865 | 141 | 4 | [
"DDInter742",
"DDInter1335"
] | Floxuridine | Omacetaxine mepesuccinate | An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection. Floxuridine is available as a sterile, nonpyrogenic, lyophilized powder for reconstitution. When administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been... | Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the pla... | Moderate | 1 | [
[
[
141,
24,
4
]
],
[
[
141,
18,
13042
],
[
13042,
46,
4
]
],
[
[
141,
7,
6628
],
[
6628,
46,
4
]
],
[
[
141,
6,
8569
],
[
8569,
57,... | [
[
[
"Floxuridine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Floxuridine",
"{u} (Compound) downregulates {v} (Gene)",
"HIST1H2BK"
],
[
"HIST1H2BK",
"{u} (Gen... | Floxuridine (Compound) downregulates HIST1H2BK (Gene) and HIST1H2BK (Gene) is upregulated by Omacetaxine mepesuccinate (Compound)
Floxuridine (Compound) upregulates PMAIP1 (Gene) and PMAIP1 (Gene) is upregulated by Omacetaxine mepesuccinate (Compound)
Floxuridine (Compound) binds TYMS (Gene) and TYMS (Gene) is downregu... |
DB00054 | DB08816 | 1,432 | 578 | [
"DDInter6",
"DDInter1802"
] | Abciximab | Ticagrelor | Abciximab is a Fab fragment of the chimeric human-murine monoclonal antibody 7E3. Abciximab binds to the glycoprotein (GP) IIb/IIIa receptor of human platelets and inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules. It also binds to vitronectin (αv... | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagre... | Moderate | 1 | [
[
[
1432,
24,
578
]
],
[
[
1432,
23,
297
],
[
297,
62,
578
]
],
[
[
1432,
64,
1578
],
[
1578,
24,
578
]
],
[
[
1432,
25,
1172
],
[
1172,
... | [
[
[
"Abciximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
]
],
[
[
"Abciximab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clove"
],
[
"Clov... | Abciximab may cause a minor interaction that can limit clinical effects when taken with Clove and Clove may cause a minor interaction that can limit clinical effects when taken with Ticagrelor
Abciximab may lead to a major life threatening interaction when taken with Lepirudin and Lepirudin may cause a moderate interac... |
DB00916 | DB09420 | 112 | 1,074 | [
"DDInter1202",
"DDInter953"
] | Metronidazole | Iodide I-123 | Metronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic infections.[A181036,A181039] Metronidazole has been used as an antibiotic for several ... | Iodide I-123 (as sodium Iodide I-123) is a radioactive isotope of iodine used in nuclear medicine for the diagnostic study of thyroid disease. Following oral administration, I-123 is absorbed through the gastrointestinal tract and is taken up by the thyroid gland. After incorporation, a gamma camera is used to detect t... | Moderate | 1 | [
[
[
112,
24,
1074
]
],
[
[
112,
64,
126
],
[
126,
24,
1074
]
],
[
[
112,
63,
10
],
[
10,
24,
1074
]
],
[
[
112,
23,
1247
],
[
1247,
... | [
[
[
"Metronidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-123"
]
],
[
[
"Metronidazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Warfarin"
],
[
"Warf... | Metronidazole may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123
Metronidazole may cause a moderate interaction that could exacerbate diseases when taken with Dapsone and Dapsone may cause a ... |
DB00371 | DB11186 | 1,050 | 1,609 | [
"DDInter1154",
"DDInter1427"
] | Meprobamate | Pentoxyverine | A carbamate with hypnotic, sedative, and some muscle relaxant properties, although in therapeutic doses reduction of anxiety rather than a direct effect may be responsible for muscle relaxation. Meprobamate has been reported to have anticonvulsant actions against petit mal seizures, but not against grand mal seizures (... | Pentoxyverine, also referred to as carbetapentane, is a non-opioid central acting antitussive with antimuscarinic, anticonvulsant , and local anesthetic properties. It is an active ingredient in over-the-counter cough suppressants in combination with guaifenesin and H1-receptor antagonists . Pentoxyverine acts on sigma... | Moderate | 1 | [
[
[
1050,
24,
1609
]
],
[
[
1050,
24,
104
],
[
104,
24,
1609
]
],
[
[
1050,
63,
701
],
[
701,
24,
1609
]
],
[
[
1050,
64,
475
],
[
475,
... | [
[
[
"Meprobamate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
]
],
[
[
"Meprobamate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
... | Meprobamate may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Meprobamate may cause a moderate interaction that could exacerbate diseases when taken with Clemastine a... |
DB00927 | DB01177 | 1,559 | 77 | [
"DDInter712",
"DDInter904"
] | Famotidine | Idarubicin | Famotidine is a competitive histamine-2 (H<sub>2</sub>) receptor antagonist that works to inhibit gastric acid secretion. It is commonly used in gastrointestinal conditions related to acid secretion, such as gastric ulcers and gastroesophageal reflux disease (GERD), in adults and children. Compared to other H<sub>2</su... | An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity. | Moderate | 1 | [
[
[
1559,
24,
77
]
],
[
[
1559,
7,
3492
],
[
3492,
46,
77
]
],
[
[
1559,
18,
10780
],
[
10780,
57,
77
]
],
[
[
1559,
21,
28803
],
[
28803,... | [
[
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idarubicin"
]
],
[
[
"Famotidine",
"{u} (Compound) upregulates {v} (Gene)",
"E2F2"
],
[
"E2F2",
"{u} (Gene) is upregulated by {v} (Com... | Famotidine (Compound) upregulates E2F2 (Gene) and E2F2 (Gene) is upregulated by Idarubicin (Compound)
Famotidine (Compound) downregulates CCNB2 (Gene) and CCNB2 (Gene) is downregulated by Idarubicin (Compound)
Famotidine (Compound) causes Anaemia (Side Effect) and Anaemia (Side Effect) is caused by Idarubicin (Compound... |
DB01174 | DB06595 | 697 | 1,491 | [
"DDInter1442",
"DDInter1214"
] | Phenobarbital | Midostaurin | A barbituric acid derivative that acts as a nonselective central nervous system depressant. It promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations. | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hem... | Major | 2 | [
[
[
697,
25,
1491
]
],
[
[
697,
25,
1135
],
[
1135,
62,
1491
]
],
[
[
697,
63,
112
],
[
112,
23,
1491
]
],
[
[
697,
24,
761
],
[
761,
... | [
[
[
"Phenobarbital",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Midostaurin"
]
],
[
[
"Phenobarbital",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"... | Phenobarbital may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Midostaurin
Phenobarbital may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole m... |
DB00197 | DB00334 | 1,324 | 867 | [
"DDInter1881",
"DDInter1326"
] | Troglitazone | Olanzapine | Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone]. | Olanzapine is a thienobenzodiazepine classified as an atypical or second-generation antipsychotic agent. The second-generation antipsychotics were introduced in the 90s and quickly gained traction due to their impressive efficacy, reduced risk for extrapyramidal side effects and reduced susceptibility to drug-drug inte... | Moderate | 1 | [
[
[
1324,
24,
867
]
],
[
[
1324,
24,
695
],
[
695,
40,
867
]
],
[
[
1324,
24,
1616
],
[
1616,
63,
867
]
],
[
[
1324,
63,
521
],
[
521,
... | [
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olanzapine"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clozapine"
],
[... | Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Clozapine and Clozapine (Compound) resembles Olanzapine (Compound)
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Histrelin and Histrelin may cause a moderate interaction that could... |
DB01285 | DB14443 | 708 | 987 | [
"DDInter445",
"DDInter1931"
] | Corticotropin | Vibrio cholerae CVD 103-HgR strain live antigen | Corticotropin (ACTH or adrenocorticotropic hormone) is a polypeptide hormone produced and secreted by the pituitary gland. It is an important player in the hypothalamic-pituitary-adrenal axis. | _Vibrio cholerae_ CVD 103-HgR strain live antigen is a component of Vaxchora, an oral vaccine for immunization against _Vibrio cholerae_ serogroup O1. Cholera is an acute bacterial disease of the small intestine caused by _Vibrio cholerae_, which is gram-negative bacteria. Two serogroups of _V. cholerae_, O1 and O139, ... | Moderate | 1 | [
[
[
708,
24,
987
]
],
[
[
708,
24,
259
],
[
259,
24,
987
]
],
[
[
708,
64,
581
],
[
581,
24,
987
]
],
[
[
708,
63,
663
],
[
663,
24,... | [
[
[
"Corticotropin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vibrio cholerae CVD 103-HgR strain live antigen"
]
],
[
[
"Corticotropin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken wi... | Corticotropin may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept and Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen
Corticotropin may lead to a major life threatening interaction when take... |
DB00289 | DB00445 | 847 | 322 | [
"DDInter132",
"DDInter655"
] | Atomoxetine | Epirubicin | Atomoxetine is a selective norepinephrine (NE) reuptake inhibitor used for the treatment of attention deficit hyperactivity disorder (ADHD). Also known as the marketed product Strattera, atomoxetine is used with other treatment modalities (psychological, educational, cognitive behaviour therapy, etc) to improve develop... | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | Moderate | 1 | [
[
[
847,
24,
322
]
],
[
[
847,
18,
1954
],
[
1954,
57,
322
]
],
[
[
847,
21,
28963
],
[
28963,
60,
322
]
],
[
[
847,
23,
112
],
[
112,
... | [
[
[
"Atomoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
]
],
[
[
"Atomoxetine",
"{u} (Compound) downregulates {v} (Gene)",
"COG2"
],
[
"COG2",
"{u} (Gene) is downregulated by {v... | Atomoxetine (Compound) downregulates COG2 (Gene) and COG2 (Gene) is downregulated by Epirubicin (Compound)
Atomoxetine (Compound) causes Anxiety (Side Effect) and Anxiety (Side Effect) is caused by Epirubicin (Compound)
Atomoxetine may cause a minor interaction that can limit clinical effects when taken with Metronidaz... |
DB00365 | DB00675 | 839 | 888 | [
"DDInter842",
"DDInter1744"
] | Grepafloxacin | Tamoxifen | Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States. | Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment ... | Major | 2 | [
[
[
839,
25,
888
]
],
[
[
839,
24,
543
],
[
543,
63,
888
]
],
[
[
839,
23,
112
],
[
112,
62,
888
]
],
[
[
839,
24,
303
],
[
303,
23,... | [
[
[
"Grepafloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tamoxifen"
]
],
[
[
"Grepafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Loperamide"
],
[
"Loper... | Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen
Grepafloxacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and ... |
DB00434 | DB01041 | 13 | 770 | [
"DDInter459",
"DDInter1789"
] | Cyproheptadine | Thalidomide | Cyproheptadine is a potent competitive antagonist of both serotonin and histamine receptors. It is used primarily to treat allergic symptoms, though it is perhaps more notable for its use in appetite stimulation and its off-label use in the treatment of serotonin syndrome. | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Moderate | 1 | [
[
[
13,
24,
770
]
],
[
[
13,
18,
7669
],
[
7669,
46,
770
]
],
[
[
13,
7,
2900
],
[
2900,
46,
770
]
],
[
[
13,
21,
28789
],
[
28789,
... | [
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
],
[
[
"Cyproheptadine",
"{u} (Compound) downregulates {v} (Gene)",
"DDIT4"
],
[
"DDIT4",
"{u} (Gene) is upregulate... | Cyproheptadine (Compound) downregulates DDIT4 (Gene) and DDIT4 (Gene) is upregulated by Thalidomide (Compound)
Cyproheptadine (Compound) upregulates NFKBIA (Gene) and NFKBIA (Gene) is upregulated by Thalidomide (Compound)
Cyproheptadine (Compound) causes Loss of consciousness (Side Effect) and Loss of consciousness (Si... |
DB01100 | DB06616 | 1,568 | 594 | [
"DDInter1470",
"DDInter224"
] | Pimozide | Bosutinib | A diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to haloperidol for the suppression of vocal and motor tics in patients with Tourette syndrome. Although the precise mechanism of action is unknown, blockade of postsynaptic dopamine receptors has been postulated. (From AMA Drug ... | Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q... | Major | 2 | [
[
[
1568,
25,
594
]
],
[
[
1568,
6,
8374
],
[
8374,
45,
594
]
],
[
[
1568,
7,
7434
],
[
7434,
46,
594
]
],
[
[
1568,
18,
15501
],
[
15501,... | [
[
[
"Pimozide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bosutinib"
]
],
[
[
"Pimozide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Bosutinib"
... | Pimozide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bosutinib (Compound)
Pimozide (Compound) upregulates HSD17B7 (Gene) and HSD17B7 (Gene) is upregulated by Bosutinib (Compound)
Pimozide (Compound) downregulates CCDC86 (Gene) and CCDC86 (Gene) is downregulated by Bosutinib (Compound)
Pimozide (Compoun... |
DB00023 | DB00356 | 305 | 1,315 | [
"DDInter127",
"DDInter366"
] | Asparaginase Escherichia coli | Chlorzoxazone | Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It also facilitates the production of oxaloacetate which is needed for general cellular metabolism. Asparaginas... | A centrally acting central muscle relaxant with sedative properties. It is claimed to inhibit muscle spasm by exerting an effect primarily at the level of the spinal cord and subcortical areas of the brain. (From Martindale, The Extra Pharmacopoea, 30th ed, p1202) | Moderate | 1 | [
[
[
305,
24,
1315
]
],
[
[
305,
24,
267
],
[
267,
63,
1315
]
],
[
[
305,
25,
770
],
[
770,
63,
1315
]
],
[
[
305,
24,
1648
],
[
1648,
... | [
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorzoxazone"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with... | Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Chlorzoxazone
Asparaginase Escherichia coli may lead to a major life threatening interaction when taken ... |
DB01087 | DB04844 | 1,520 | 843 | [
"DDInter1520",
"DDInter1778"
] | Primaquine | Tetrabenazine | An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Ad... | A drug formerly used as an antipsychotic but now used primarily in the symptomatic treatment of various hyperkinetic disorders. It is a monoamine depletor and used as symptomatic treatment of chorea associated with Huntington's disease. FDA approved on August 15, 2008. | Moderate | 1 | [
[
[
1520,
24,
843
]
],
[
[
1520,
62,
479
],
[
479,
40,
843
]
],
[
[
1520,
6,
12523
],
[
12523,
45,
843
]
],
[
[
1520,
21,
28852
],
[
28852... | [
[
[
"Primaquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetrabenazine"
]
],
[
[
"Primaquine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Donepezil"
],
[
... | Primaquine may cause a minor interaction that can limit clinical effects when taken with Donepezil and Donepezil (Compound) resembles Tetrabenazine (Compound)
Primaquine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Tetrabenazine (Compound)
Primaquine (Compound) causes Leukopenia (Side Effect) and Leukop... |
DB00448 | DB01319 | 1,215 | 34 | [
"DDInter1022",
"DDInter777"
] | Lansoprazole | Fosamprenavir | Lansoprazole marketed under the brand Prevacid, is a proton pump inhibitor (PPI) and is structurally classified as a substituted benzimidazole. It reduces gastric acid secretion by targeting gastric H,K-ATPase pumps and is thus effective at promoting healing in ulcerative diseases, and treating gastroesophageal reflux ... | Fosamprenavir is a prodrug of amprenavir, an inhibitor of human immunodeficiency virus (HIV) protease. | Moderate | 1 | [
[
[
1215,
24,
34
]
],
[
[
1215,
6,
8374
],
[
8374,
45,
34
]
],
[
[
1215,
21,
29062
],
[
29062,
60,
34
]
],
[
[
1215,
24,
609
],
[
609,
... | [
[
[
"Lansoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosamprenavir"
]
],
[
[
"Lansoprazole",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Comp... | Lansoprazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Fosamprenavir (Compound)
Lansoprazole (Compound) causes Neutropenia (Side Effect) and Neutropenia (Side Effect) is caused by Fosamprenavir (Compound)
Lansoprazole may cause a moderate interaction that could exacerbate diseases when taken with Cla... |
DB04908 | DB11901 | 1,671 | 913 | [
"DDInter741",
"DDInter107"
] | Flibanserin | Apalutamide | Flibanserin is the first drug to be approved for hypoactive sexual desire disorder (HSDD) in premenopausal women by the FDA in August 2015. It was originally developed as an antidepressant medication by Boehringer Ingelheim, but showed lack of efficacy in trials and was further developed as a hypoactive sexual disorder... | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Res... | Major | 2 | [
[
[
1671,
25,
913
]
],
[
[
1671,
64,
600
],
[
600,
24,
913
]
],
[
[
1671,
63,
303
],
[
303,
24,
913
]
],
[
[
1671,
24,
1320
],
[
1320,
... | [
[
[
"Flibanserin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apalutamide"
]
],
[
[
"Flibanserin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"... | Flibanserin may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Flibanserin may cause a moderate interaction that could exacerbate diseases when taken with Medroxyprogesterone acetate and... |
DB00393 | DB00486 | 854 | 1,614 | [
"DDInter1295",
"DDInter1253"
] | Nimodipine | Nabilone | Nimodipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nimodipine prevents calcium-dependent smooth muscle contraction ... | Nabilone (marketed as Cesamet) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). Although structurally distinct from THC, nabilone mimics THC's structure and pharmacological activity through weak partial agonist activity at Cannabinoid-1 (CB1R) and... | Moderate | 1 | [
[
[
854,
24,
1614
]
],
[
[
854,
24,
530
],
[
530,
1,
1614
]
],
[
[
854,
21,
28863
],
[
28863,
60,
1614
]
],
[
[
854,
63,
999
],
[
999,
... | [
[
[
"Nimodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nabilone"
]
],
[
[
"Nimodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronabinol"
],
[
... | Nimodipine may cause a moderate interaction that could exacerbate diseases when taken with Dronabinol and Dronabinol (Compound) resembles Nabilone (Compound)
Nimodipine (Compound) causes Lightheadedness (Side Effect) and Lightheadedness (Side Effect) is caused by Nabilone (Compound)
Nimodipine may cause a moderate inte... |
DB00308 | DB01611 | 347 | 1,487 | [
"DDInter901",
"DDInter893"
] | Ibutilide | Hydroxychloroquine | Ibutilide is a Class III antiarrhythmic agent available in intravenous formulations. It is indicated for the conversion of acute atrial flutter and recent onset atrial fibrillation to normal sinus rhythm (NSR). | Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like [chloroquine]. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxyc... | Major | 2 | [
[
[
347,
25,
1487
]
],
[
[
347,
25,
1520
],
[
1520,
25,
1487
]
],
[
[
347,
21,
28789
],
[
28789,
60,
1487
]
],
[
[
347,
24,
286
],
[
286,
... | [
[
[
"Ibutilide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydroxychloroquine"
]
],
[
[
"Ibutilide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Primaquine"
],
[
"Primaquine",
... | Ibutilide may lead to a major life threatening interaction when taken with Primaquine and Primaquine may lead to a major life threatening interaction when taken with Hydroxychloroquine
Ibutilide (Compound) causes Loss of consciousness (Side Effect) and Loss of consciousness (Side Effect) is caused by Hydroxychloroquine... |
DB00461 | DB00574 | 598 | 121 | [
"DDInter1254",
"DDInter717"
] | Nabumetone | Fenfluramine | Nabumetone was originally developed as a non-acidic non-steroidal anti-inflammatory drug (NSAID).[label] It was thought to avoid trapping of the drug in the stomach by making it unable to dissociate into ions which was believed to reduce GI toxicity by limiting local action. While slightly reduced, possibly due to a de... | Dravet syndrome is a pediatric encephalopathy that typically manifests within the first year of life following exposure to elevated temperatures. It is characterized by recurrent pharmacoresistant seizures, which increase in frequency and severity with disease progression. Concomitantly with these seizures, patients ty... | Moderate | 1 | [
[
[
598,
24,
121
]
],
[
[
598,
24,
1144
],
[
1144,
63,
121
]
],
[
[
598,
63,
366
],
[
366,
24,
121
]
],
[
[
598,
25,
292
],
[
292,
6... | [
[
[
"Nabumetone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fenfluramine"
]
],
[
[
"Nabumetone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
],
[... | Nabumetone may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Fenfluramine
Nabumetone may cause a moderate interaction that could exacerbate diseases when taken with Eptifibatide and ... |
DB01320 | DB12267 | 651 | 1,476 | [
"DDInter783",
"DDInter233"
] | Fosphenytoin | Brigatinib | Fosphenytoin is a water-soluble phenytoin prodrug used only in hospitals for the treatment of epileptic seizures. It works by slowing down impulses in the brain that cause seizures. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repe... | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Major | 2 | [
[
[
651,
25,
1476
]
],
[
[
651,
25,
1135
],
[
1135,
23,
1476
]
],
[
[
651,
64,
168
],
[
168,
23,
1476
]
],
[
[
651,
64,
629
],
[
629,
... | [
[
[
"Fosphenytoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brigatinib"
]
],
[
[
"Fosphenytoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u}... | Fosphenytoin may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Fosphenytoin may lead to a major life threatening interaction when taken with Bortezomib and Bortezomib may cause a minor interac... |
DB00889 | DB11952 | 1,133 | 800 | [
"DDInter840",
"DDInter612"
] | Granisetron | Duvelisib | A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant for cancer chemotherapy patients. | Duvelisib, also known as IPI-145 and INK-1197, is a small-molecule inhibitor of phosphoinositide-3 kinases that was designed initially to prove that simultaneous inhibition of the isoforms delta and gamma can produce a broad adaptative and innate immune cell inhibitory activity. All the work around duvelisib showed tha... | Moderate | 1 | [
[
[
1133,
24,
800
]
],
[
[
1133,
25,
222
],
[
222,
23,
800
]
],
[
[
1133,
24,
1476
],
[
1476,
63,
800
]
],
[
[
1133,
63,
1324
],
[
1324,
... | [
[
[
"Granisetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Duvelisib"
]
],
[
[
"Granisetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sibutramine"
],
[
"Sibutram... | Granisetron may lead to a major life threatening interaction when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Duvelisib
Granisetron may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause... |
DB06589 | DB11730 | 1,250 | 351 | [
"DDInter1400",
"DDInter1588"
] | Pazopanib | Ribociclib | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | Major | 2 | [
[
[
1250,
25,
351
]
],
[
[
1250,
24,
466
],
[
466,
62,
351
]
],
[
[
1250,
62,
1247
],
[
1247,
23,
351
]
],
[
[
1250,
23,
907
],
[
907,
... | [
[
[
"Pazopanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
]
],
[
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
[
"Darolutami... | Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Pazopanib may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Su... |
DB00065 | DB16582 | 581 | 899 | [
"DDInter923",
"DDInter1080"
] | Infliximab | Lisocabtagene maraleucel | Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory ... | Lisocabtagene maraleucel is a chimeric antigen receptor (CAR) T-cell therapy, similar to [brexucabtagene autoleucel] and [axicabtagene ciloleucel].[A228493,L31588] Lisocabtagene maraleucel is a genetically modified autologous T-cell therapy that targets CD19, the B-lymphocyte surface antigen B4. CAR T-cell therapy has ... | Major | 2 | [
[
[
581,
25,
899
]
],
[
[
581,
25,
869
],
[
869,
24,
899
]
],
[
[
581,
24,
1430
],
[
1430,
24,
899
]
],
[
[
581,
25,
676
],
[
676,
2... | [
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lisocabtagene maraleucel"
]
],
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Topotecan"
],
[
"Topotecan",
... | Infliximab may lead to a major life threatening interaction when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Lisocabtagene maraleucel
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipuleu... |
DB09128 | DB13928 | 1,241 | 1,385 | [
"DDInter231",
"DDInter1660"
] | Brexpiprazole | Semaglutide | Brexpiprazole is an atypical antipsychotic and a novel D2 dopamine and serotonin 1A partial agonist called serotonin-dopamine activity modulator (SDAM). It has a high affinity for serotonin, dopamine and alpha (α)-adrenergic receptors. Although it is structurally similar to [aripiprazole], brexpiprazole has different b... | Semaglutide is a glucagon-like peptide 1 (GLP-1) analog used to manage type 2 diabetes along with lifestyle changes, such as dietary restrictions and increased physical activity.[A31421,L8681] Other members of this drug class include [Exenatide] and [Liraglutide]. Semaglutide was developed by Novo Nordisk and approved ... | Moderate | 1 | [
[
[
1241,
24,
1385
]
],
[
[
1241,
24,
1476
],
[
1476,
24,
1385
]
],
[
[
1241,
63,
1144
],
[
1144,
24,
1385
]
],
[
[
1241,
64,
609
],
[
609... | [
[
[
"Brexpiprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Semaglutide"
]
],
[
[
"Brexpiprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
],
... | Brexpiprazole may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Brexpiprazole may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide an... |
DB01076 | DB04868 | 700 | 478 | [
"DDInter133",
"DDInter1293"
] | Atorvastatin | Nilotinib | Atorvastatin (Lipitor®), is a lipid-lowering drug included in the statin class of medications. By inhibiting the endogenous production of cholesterol in the liver, statins lower abnormal cholesterol and lipid levels, and ultimately reduce the risk of cardiovascular disease. More specifically, statin medications competi... | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Moderate | 1 | [
[
[
700,
24,
478
]
],
[
[
700,
24,
1468
],
[
1468,
63,
478
]
],
[
[
700,
6,
6017
],
[
6017,
45,
478
]
],
[
[
700,
7,
7669
],
[
7669,
... | [
[
[
"Atorvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
]
],
[
[
"Atorvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
],
[
... | Atorvastatin may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Atorvastatin (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Nilotinib (Compound)
Atorvastatin (Comp... |
DB00358 | DB01115 | 1,010 | 336 | [
"DDInter1140",
"DDInter1291"
] | Mefloquine | Nifedipine | Malaria is a protozoan disease that places an enormous burden on human health in endemic areas around the world. The 2020 World Health Organization malaria report indicates a 60% decrease in the global malaria fatality rate between 2000 to 2019. Despite this, malaria remains a significant cause of morbidity and mortali... | Nifedipine, or BAY a 1040, is a first generation dihydropyridine L-type calcium channel blocker, similar to [nicardipine].[A190210,A190273,A175390,L11383] Nifedipine was developed by Bayer and first described in the literature, along with other dihydropyridines, in 1972.[A175390,A190276] Since nifedipine's development,... | Moderate | 1 | [
[
[
1010,
24,
336
]
],
[
[
1010,
63,
1428
],
[
1428,
1,
336
]
],
[
[
1010,
24,
1081
],
[
1081,
40,
336
]
],
[
[
1010,
24,
376
],
[
376,
... | [
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nifedipine"
]
],
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isradipine"
],
[
... | Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Isradipine and Isradipine (Compound) resembles Nifedipine (Compound)
Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Nicardipine and Nicardipine (Compound) resembles Nifedipine (Compound... |
DB00924 | DB11730 | 1,405 | 351 | [
"DDInter454",
"DDInter1588"
] | Cyclobenzaprine | Ribociclib | Cyclobenzaprine, a centrally-acting muscle relaxant, was first synthesized in 1961 and has been available for human use since 1977. It was initially studied for use as antidepressant given its structural similarity to tricyclic antidepressants - it differs from [Amitriptyline] by only a single double bond.[A185039,A184... | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | Moderate | 1 | [
[
[
1405,
24,
351
]
],
[
[
1405,
24,
222
],
[
222,
23,
351
]
],
[
[
1405,
24,
1532
],
[
1532,
24,
351
]
],
[
[
1405,
63,
723
],
[
723,
... | [
[
[
"Cyclobenzaprine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
]
],
[
[
"Cyclobenzaprine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
... | Cyclobenzaprine may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Cyclobenzaprine may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide ... |
DB00023 | DB01033 | 305 | 328 | [
"DDInter127",
"DDInter1156"
] | Asparaginase Escherichia coli | Mercaptopurine | Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It also facilitates the production of oxaloacetate which is needed for general cellular metabolism. Asparaginas... | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | Moderate | 1 | [
[
[
305,
24,
328
]
],
[
[
305,
24,
1299
],
[
1299,
23,
328
]
],
[
[
305,
24,
126
],
[
126,
24,
328
]
],
[
[
305,
63,
1257
],
[
1257,
... | [
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mercaptopurine"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken wit... | Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Trovafloxacin and Trovafloxacin may cause a minor interaction that can limit clinical effects when taken with Mercaptopurine
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate ... |
DB00361 | DB09570 | 134 | 1,480 | [
"DDInter1939",
"DDInter1002"
] | Vinorelbine | Ixazomib | Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC). It was initially approved in the USA in 1990's for the treatment of NSCLC. It is a third-generation vinca alkaloid. The introduction of third-g... | Ixazomib a second generation proteasome inhibitor (PI) and the first oral PI approved by the FDA in November 2015 for multiple myeloma treatment in combination with 2 other therapies (lenalidomide and dexamethasone) for patients who have received at least 1 prior therapy. It was found to have similar efficacy to bortez... | Moderate | 1 | [
[
[
134,
24,
1480
]
],
[
[
134,
24,
987
],
[
987,
63,
1480
]
],
[
[
134,
63,
440
],
[
440,
24,
1480
]
],
[
[
134,
24,
453
],
[
453,
... | [
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixazomib"
]
],
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vibrio cholerae CVD 103-HgR... | Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen and Vibrio cholerae CVD 103-HgR strain live antigen may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib
Vinorelbine may cause a moderate intera... |
DB00087 | DB01056 | 599 | 571 | [
"DDInter41",
"DDInter1823"
] | Alemtuzumab | Tocainide | Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52. The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant region... | An antiarrhythmic agent which exerts a potential- and frequency-dependent block of sodium channels. | Moderate | 1 | [
[
[
599,
24,
571
]
],
[
[
599,
25,
976
],
[
976,
63,
571
]
],
[
[
599,
24,
270
],
[
270,
63,
571
]
],
[
[
599,
25,
1292
],
[
1292,
6... | [
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tocainide"
]
],
[
[
"Alemtuzumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofaciti... | Alemtuzumab may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Tocainide
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may c... |
DB05528 | DB08901 | 1,070 | 1,468 | [
"DDInter1228",
"DDInter1492"
] | Mipomersen | Ponatinib | Mipomersen sodium, which was known as the investigational drug, isis-301012, is the salt form of a synthetic phosphorothioate oligonucleotide. Mipomersen sodium prevents the formation of apo B-100, resulting in a decrease in the levels of apolipoprotein B (apo B), low density lipoprotein (LDL), and total cholesterol. M... | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Major | 2 | [
[
[
1070,
25,
1468
]
],
[
[
1070,
64,
478
],
[
478,
24,
1468
]
],
[
[
1070,
25,
384
],
[
384,
63,
1468
]
],
[
[
1070,
25,
850
],
[
850,
... | [
[
[
"Mipomersen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ponatinib"
]
],
[
[
"Mipomersen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} may ... | Mipomersen may lead to a major life threatening interaction when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Mipomersen may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib may cause a moderate interac... |
DB01124 | DB08881 | 1,411 | 868 | [
"DDInter1828",
"DDInter1925"
] | Tolbutamide | Vemurafenib | Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release... | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Moderate | 1 | [
[
[
1411,
24,
868
]
],
[
[
1411,
7,
3422
],
[
3422,
46,
868
]
],
[
[
1411,
18,
2423
],
[
2423,
57,
868
]
],
[
[
1411,
7,
3771
],
[
3771,
... | [
[
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
]
],
[
[
"Tolbutamide",
"{u} (Compound) upregulates {v} (Gene)",
"SATB1"
],
[
"SATB1",
"{u} (Gene) is upregulated by {v}... | Tolbutamide (Compound) upregulates SATB1 (Gene) and SATB1 (Gene) is upregulated by Vemurafenib (Compound)
Tolbutamide (Compound) downregulates PSMD2 (Gene) and PSMD2 (Gene) is downregulated by Vemurafenib (Compound)
Tolbutamide (Compound) upregulates SUV39H1 (Gene) and SUV39H1 (Gene) is downregulated by Vemurafenib (Co... |
DB06372 | DB09331 | 259 | 745 | [
"DDInter1594",
"DDInter478"
] | Rilonacept | Daratumumab | Rilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein linked to the Fc portion of immunoglobulin G1. Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as cryopyrin-associated periodic syndromes, including familial cold au... | Daratumumab is an immunoglobulin G1 kappa monoclonal antibody developed by Janssen and Genmab. It was first described in the literature in 2010 as a monoclonal antibody that targets CD38+ multiple myeloma cells; the first of its kind. Daratumumab was granted FDA approval on 16 November 2015. It is approved for the trea... | Moderate | 1 | [
[
[
259,
24,
745
]
],
[
[
259,
63,
139
],
[
139,
24,
745
]
],
[
[
259,
24,
287
],
[
287,
63,
745
]
],
[
[
259,
24,
1362
],
[
1362,
2... | [
[
[
"Rilonacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Daratumumab"
]
],
[
[
"Rilonacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zidovudine"
],
[
... | Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Zidovudine and Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Daratumumab
Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate a... |
DB00196 | DB01208 | 600 | 945 | [
"DDInter743",
"DDInter1705"
] | Fluconazole | Sparfloxacin | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole ... | Sparfloxacin is a fluoroquinolone antibiotic indicated for bacterial infections. Sparfloxacin exerts its antibacterial activity by inhibiting DNA gyrase, a bacterial topoisomerase. DNA gyrase is an essential enzyme which controls DNA topology and assists in DNA replication, repair, deactivation, and transcription. | Major | 2 | [
[
[
600,
25,
945
]
],
[
[
600,
24,
739
],
[
739,
1,
945
]
],
[
[
600,
25,
1176
],
[
1176,
1,
945
]
],
[
[
600,
6,
4973
],
[
4973,
45... | [
[
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sparfloxacin"
]
],
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomefloxacin"
],
[
"Lome... | Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Lomefloxacin and Lomefloxacin (Compound) resembles Sparfloxacin (Compound)
Fluconazole may lead to a major life threatening interaction when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Sparfloxacin (Compound)
F... |
DB00344 | DB04837 | 1,302 | 649 | [
"DDInter1543",
"DDInter407"
] | Protriptyline | Clofedanol | Protriptyline hydrochloride is a dibenzocycloheptene-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, protriptyline does not affect mood or arousal, but may ... | Clofedanol is a centrally-acting cough suppressant available in Canada under the trade name Ulone. It is not available in the United States. | Moderate | 1 | [
[
[
1302,
24,
649
]
],
[
[
1302,
24,
1376
],
[
1376,
24,
649
]
],
[
[
1302,
1,
1405
],
[
1405,
24,
649
]
],
[
[
1302,
24,
832
],
[
832,
... | [
[
[
"Protriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
]
],
[
[
"Protriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
... | Protriptyline may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol
Protriptyline (Compound) resembles Cyclobenzaprine (Compound) and Cyclobenzaprine may cause a moder... |
DB00218 | DB12141 | 1,176 | 971 | [
"DDInter1247",
"DDInter817"
] | Moxifloxacin | Gilteritinib | Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment. | Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression... | Major | 2 | [
[
[
1176,
25,
971
]
],
[
[
1176,
23,
112
],
[
112,
23,
971
]
],
[
[
1176,
25,
485
],
[
485,
24,
971
]
],
[
[
1176,
25,
823
],
[
823,
... | [
[
[
"Moxifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gilteritinib"
]
],
[
[
"Moxifloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Met... | Moxifloxacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Moxifloxacin may lead to a major life threatening interaction when taken with Pentamidine and Pentamidine ... |
DB00450 | DB09078 | 78 | 1,228 | [
"DDInter603",
"DDInter1036"
] | Droperidol | Lenvatinib | A butyrophenone with general properties similar to those of haloperidol. It is used in conjunction with an opioid analgesic such as fentanyl to maintain the patient in a calm state of neuroleptanalgesia with indifference to surroundings but still able to cooperate with the surgeon. It is also used as a premedicant, as ... | Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progressi... | Major | 2 | [
[
[
78,
25,
1228
]
],
[
[
78,
23,
112
],
[
112,
23,
1228
]
],
[
[
78,
25,
609
],
[
609,
24,
1228
]
],
[
[
78,
24,
770
],
[
770,
24,
... | [
[
[
"Droperidol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lenvatinib"
]
],
[
[
"Droperidol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronida... | Droperidol may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lenvatinib
Droperidol may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin ... |
DB00454 | DB00787 | 1,349 | 387 | [
"DDInter1150",
"DDInter25"
] | Meperidine | Acyclovir | A narcotic analgesic that can be used for the relief of most types of moderate to severe pain, including postoperative pain and the pain of labor. Prolonged use may lead to dependence of the morphine type; withdrawal symptoms appear more rapidly than with morphine and are of shorter duration. | Acyclovir is a nucleotide analog antiviral used to treat herpes simplex, _Varicella zoster_, herpes zoster, herpes labialis, and acute herpetic keratitis[L7303,L7315,L7318,L7321,L7324,L7327]. Acyclovir is generally used first line in the treatment of these viruses and some products are indicated for patients as young a... | Moderate | 1 | [
[
[
1349,
24,
387
]
],
[
[
1349,
21,
29118
],
[
29118,
60,
387
]
],
[
[
1349,
24,
1532
],
[
1532,
63,
387
]
],
[
[
1349,
63,
352
],
[
352,... | [
[
[
"Meperidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acyclovir"
]
],
[
[
"Meperidine",
"{u} (Compound) causes {v} (Side Effect)",
"Tachycardia"
],
[
"Tachycardia",
"{u} (Side Effect) is c... | Meperidine (Compound) causes Tachycardia (Side Effect) and Tachycardia (Side Effect) is caused by Acyclovir (Compound)
Meperidine may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Acyc... |
DB00987 | DB15091 | 1,224 | 676 | [
"DDInter460",
"DDInter1901"
] | Cytarabine | Upadacitinib | A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant p... | Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by syn... | Major | 2 | [
[
[
1224,
25,
676
]
],
[
[
1224,
63,
1461
],
[
1461,
23,
676
]
],
[
[
1224,
24,
1430
],
[
1430,
24,
676
]
],
[
[
1224,
63,
597
],
[
597,
... | [
[
[
"Cytarabine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Cytarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitamin E... | Cytarabine may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Upadacitinib
Cytarabine may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipule... |
DB00361 | DB11901 | 134 | 913 | [
"DDInter1939",
"DDInter107"
] | Vinorelbine | Apalutamide | Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC). It was initially approved in the USA in 1990's for the treatment of NSCLC. It is a third-generation vinca alkaloid. The introduction of third-g... | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Res... | Moderate | 1 | [
[
[
134,
24,
913
]
],
[
[
134,
24,
112
],
[
112,
23,
913
]
],
[
[
134,
24,
110
],
[
110,
62,
913
]
],
[
[
134,
63,
600
],
[
600,
24,... | [
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
... | Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Apalutamide
Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Polatuzumab ve... |
DB00705 | DB06605 | 441 | 1,409 | [
"DDInter496",
"DDInter108"
] | Delavirdine | Apixaban | A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1. | Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FD... | Moderate | 1 | [
[
[
441,
24,
1409
]
],
[
[
441,
6,
3486
],
[
3486,
45,
1409
]
],
[
[
441,
21,
28787
],
[
28787,
60,
1409
]
],
[
[
441,
25,
1670
],
[
1670,... | [
[
[
"Delavirdine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apixaban"
]
],
[
[
"Delavirdine",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (Compound)",... | Delavirdine (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Apixaban (Compound)
Delavirdine (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Apixaban (Compound)
Delavirdine may lead to a major life threatening interaction when taken with Eliglustat and Eliglustat may cau... |
DB11560 | DB12001 | 1,678 | 564 | [
"DDInter1038",
"DDInter7"
] | Lesinurad | Abemaciclib | Lesinurad is an oral uric acid transporter 1 (URAT1) inhibitor indicated for the treatment of hyperuricemia associated with gout. It reduces serum uric acid concentration through the inhibition of URAT1, an enzyme responsible for reuptake of uric acid from the renal tubule, and OAT4, another uric acid transporter assoc... | Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity. On September 28, 2017, FDA granted approval of abemaciclib treatment under the market name Verzenio for the trea... | Moderate | 1 | [
[
[
1678,
24,
564
]
],
[
[
1678,
63,
868
],
[
868,
24,
564
]
],
[
[
1678,
24,
1017
],
[
1017,
63,
564
]
],
[
[
1678,
24,
351
],
[
351,
... | [
[
[
"Lesinurad",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abemaciclib"
]
],
[
[
"Lesinurad",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
],
[
... | Lesinurad may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Abemaciclib
Lesinurad may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorla... |
DB01064 | DB06288 | 1,148 | 607 | [
"DDInter987",
"DDInter77"
] | Isoprenaline | Amisulpride | Isoprenaline is a non-selective beta adrenergic receptor agonist indicated to treat heart block, Adams-Stokes attacks, bronchospasm in anesthesia, cadiac arrest, hypovolemic shocks, septic shock, hypoperfusion, congestive hear failure, and cardiogenic shock.[A15638,L33160] Isoprenaline research in the 1940s found that ... | Amisulpride is a benzamide derivative and a dopamine receptor antagonist that selectively works on dopamine D2 and D3 receptors. As an antipsychotic agent, amisulpride alleviates both positive and negative symptoms of schizophrenia, and it exhibits antidepressant properties in patients with psychiatric disorders, dysth... | Major | 2 | [
[
[
1148,
25,
607
]
],
[
[
1148,
21,
28714
],
[
28714,
60,
607
]
],
[
[
1148,
63,
1559
],
[
1559,
24,
607
]
],
[
[
1148,
62,
870
],
[
870,... | [
[
[
"Isoprenaline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amisulpride"
]
],
[
[
"Isoprenaline",
"{u} (Compound) causes {v} (Side Effect)",
"Asthenia"
],
[
"Asthenia",
"{u} (Side Effect) is caused by {v} (C... | Isoprenaline (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Amisulpride (Compound)
Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Famotidine and Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Amis... |
DB00812 | DB08875 | 998 | 1,618 | [
"DDInter1451",
"DDInter262"
] | Phenylbutazone | Cabozantinib | A drug that has anti-inflammatory, antipyretic, and analgesic activities. It is especially effective in the treatment of ankylosing spondylitis. It also is useful in rheumatoid arthritis and Reiter's syndrome (investigational indication). Although phenylbutazone is effective in gouty arthritis, risk/benefit conside... | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Major | 2 | [
[
[
998,
25,
1618
]
],
[
[
998,
24,
1135
],
[
1135,
62,
1618
]
],
[
[
998,
63,
723
],
[
723,
24,
1618
]
],
[
[
998,
24,
384
],
[
384,
... | [
[
[
"Phenylbutazone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
]
],
[
[
"Phenylbutazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxegol"
],
[
"N... | Phenylbutazone may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Cabozantinib
Phenylbutazone may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and ... |
DB00774 | DB09135 | 1,577 | 1,211 | [
"DDInter889",
"DDInter967"
] | Hydroflumethiazide | Ioxilan | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p822) | Ioxilan is a tri-iodinated diagnostic contrast agent. Intravascular injection results in opacification of vessels in the path of flow of the contrast medium, permitting radiographic visualization of the internal structures of the human body until significant hemodilution occurs. | Moderate | 1 | [
[
[
1577,
24,
1211
]
],
[
[
1577,
1,
323
],
[
323,
24,
1211
]
],
[
[
1577,
40,
674
],
[
674,
24,
1211
]
],
[
[
1577,
63,
1648
],
[
1648,
... | [
[
[
"Hydroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ioxilan"
]
],
[
[
"Hydroflumethiazide",
"{u} (Compound) resembles {v} (Compound)",
"Bendroflumethiazide"
],
[
"Bendroflumethiazide",... | Hydroflumethiazide (Compound) resembles Bendroflumethiazide (Compound) and Bendroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Ioxilan
Hydroflumethiazide (Compound) resembles Trichlormethiazide (Compound) and Trichlormethiazide may cause a moderate interaction that could ... |
DB00238 | DB00317 | 188 | 883 | [
"DDInter1285",
"DDInter810"
] | Nevirapine | Gefitinib | A potent, non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with nucleoside analogues for treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection and AIDS. Structurally, nevirapine belongs to the dipyridodiazepinone chemical class. | Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa. | Moderate | 1 | [
[
[
188,
24,
883
]
],
[
[
188,
24,
594
],
[
594,
40,
883
]
],
[
[
188,
24,
1195
],
[
1195,
1,
883
]
],
[
[
188,
6,
12523
],
[
12523,
... | [
[
[
"Nevirapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gefitinib"
]
],
[
[
"Nevirapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
],
[
... | Nevirapine may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib and Bosutinib (Compound) resembles Gefitinib (Compound)
Nevirapine may cause a moderate interaction that could exacerbate diseases when taken with Erlotinib and Erlotinib (Compound) resembles Gefitinib (Compound)
Nevira... |
DB00405 | DB09117 | 128 | 957 | [
"DDInter517",
"DDInter1391"
] | Dexbrompheniramine | Paraldehyde | Dexbrompheniramine maleate is an antihistamine agent that is used for the treatment of allergic conditions, such as hay fever or urticaria. | Paraldehyde was initially introduced into medical practice in the United Kingdom in 1882 by the Italian physician Vincenzo Cervello. It is classified as a central nervous system (CNS) depressant and has also been found to be an effective anticonvulsant, hypnotic and sedative agent due to its CNS depressant properties. ... | Moderate | 1 | [
[
[
128,
24,
957
]
],
[
[
128,
24,
1264
],
[
1264,
24,
957
]
],
[
[
128,
74,
1594
],
[
1594,
24,
957
]
],
[
[
128,
24,
1609
],
[
1609,
... | [
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paraldehyde"
]
],
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
... | Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Paraldehyde
Dexbrompheniramine (Compound) resembles Doxylamine (Compound) and Dexbrompheniramine may cause a moderate int... |
DB11569 | DB14881 | 1,093 | 180 | [
"DDInter1003",
"DDInter1329"
] | Ixekizumab | Oliceridine | Ixekizumab is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody (mAb) against interleukin-17A (IL-17A) and prevents it from interacting with the IL-17A receptor. As IL-17A is a pro-inflammatory cytokine involved in inflammation and immune responses, blocking its effect is beneficial for use in inflamma... | Severe acute pain occurs through nociceptive signalling involving both ascending and descending spinal pathways, in which nerve conductance is mediated in part by the action of opioid receptors.[A218041, A218046] Opioid receptors are seven-transmembrane G-protein-coupled receptors (GPCRs), of which the μ-opioid recepto... | Moderate | 1 | [
[
[
1093,
24,
180
]
],
[
[
1093,
63,
1184
],
[
1184,
24,
180
]
],
[
[
1093,
64,
375
],
[
375,
24,
180
]
],
[
[
1093,
25,
1259
],
[
1259,
... | [
[
[
"Ixekizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oliceridine"
]
],
[
[
"Ixekizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anakinra"
],
[
... | Ixekizumab may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Ixekizumab may lead to a major life threatening interaction when taken with Certolizumab pegol and Certolizumab peg... |
DB00775 | DB04932 | 1,226 | 1,564 | [
"DDInter1818",
"DDInter491"
] | Tirofiban | Defibrotide | Tirofiban prevents the blood from clotting during episodes of chest pain or a heart attack, or while the patient is undergoing a procedure to treat a blocked coronary artery. It is a non-peptide reversible antagonist of the platelet glycoprotein (GP) IIb/IIIa receptor, and inhibits platelet aggregation. | Defibrotide is the sodium salt of a mixture of single-stranded oligodeoxyribonucleotides derived from porcine mucosal DNA. It has been shown to have antithrombotic, anti-inflammatory and anti-ischemic properties (but without associated significant systemic anticoagulant effects). It is marketed under the brand names Da... | Major | 2 | [
[
[
1226,
25,
1564
]
],
[
[
1226,
23,
297
],
[
297,
62,
1564
]
],
[
[
1226,
24,
914
],
[
914,
24,
1564
]
],
[
[
1226,
63,
1100
],
[
1100,
... | [
[
[
"Tirofiban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Defibrotide"
]
],
[
[
"Tirofiban",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clove"
],
[
"Clove",
"{u}... | Tirofiban may cause a minor interaction that can limit clinical effects when taken with Clove and Clove may cause a minor interaction that can limit clinical effects when taken with Defibrotide
Tirofiban may cause a moderate interaction that could exacerbate diseases when taken with Diflunisal and Diflunisal may cause ... |
DB00017 | DB14509 | 1,505 | 1,399 | [
"DDInter1636",
"DDInter1081"
] | Salmon calcitonin | Lithium carbonate | Synthetic peptide, 32 residues long formulated as a nasal spray. | Lithium has been used to treat manic episodes since the 19th century. Though it is widely used, its mechanism of action is still unknown[FDA Label][A14585,A176642,A176651,L5843]. Lithium carbonate has a narrow therapeutic range and so careful monitoring is required to avoid adverse effects[FDA Label]. | Moderate | 1 | [
[
[
1505,
24,
1399
]
],
[
[
1505,
23,
475
],
[
475,
24,
1399
]
],
[
[
1505,
23,
752
],
[
752,
23,
112
],
[
112,
24,
1399
]
],
[
[
1505,
... | [
[
[
"Salmon calcitonin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Salmon calcitonin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Morphine... | Salmon calcitonin may cause a minor interaction that can limit clinical effects when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate
Salmon calcitonin may cause a minor interaction that can limit clinical effects when taken with Cimetidi... |
DB00359 | DB00414 | 161 | 590 | [
"DDInter1721",
"DDInter16"
] | Sulfadiazine | Acetohexamide | One of the short-acting sulfonamides used in combination with pyrimethamine to treat toxoplasmosis in patients with acquired immunodeficiency syndrome and in newborns with congenital infections. | A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market. | Moderate | 1 | [
[
[
161,
24,
590
]
],
[
[
161,
1,
50
],
[
50,
63,
590
]
],
[
[
161,
63,
176
],
[
176,
24,
590
]
],
[
[
161,
1,
1029
],
[
1029,
24,
... | [
[
[
"Sulfadiazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetohexamide"
]
],
[
[
"Sulfadiazine",
"{u} (Compound) resembles {v} (Compound)",
"Sulfasalazine"
],
[
"Sulfasalazine",
"{u} may ca... | Sulfadiazine (Compound) resembles Sulfasalazine (Compound) and Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide
Sulfadiazine may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and Insulin glargine may cause a modera... |
DB00019 | DB11793 | 1,257 | 738 | [
"DDInter1405",
"DDInter1297"
] | Pegfilgrastim | Niraparib | Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, [filgrastim]. The drug is approved for use to decrease the incidence of infection, as manifested by febrile neutropenia, in susceptible patients with with non-myeloid cancer receiving myelosuppressive anti... | Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, f... | Moderate | 1 | [
[
[
1257,
24,
738
]
],
[
[
1257,
24,
1213
],
[
1213,
24,
738
]
],
[
[
1257,
24,
1619
],
[
1619,
63,
738
]
],
[
[
1257,
63,
491
],
[
491,
... | [
[
[
"Pegfilgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
]
],
[
[
"Pegfilgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
],
... | Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Ruca... |
DB00865 | DB00902 | 939 | 104 | [
"DDInter187",
"DDInter1168"
] | Benzphetamine | Methdilazine | A sympathomimetic agent with properties similar to dextroamphetamine. It is used in the treatment of obesity. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1222) | Methdilazine is a phenothiazine compound with antihistaminic activity. It is used in the treatment of various dermatoses to relieve pruritus. | Moderate | 1 | [
[
[
939,
24,
104
]
],
[
[
939,
40,
11286
],
[
11286,
1,
104
]
],
[
[
939,
24,
820
],
[
820,
1,
104
]
],
[
[
939,
1,
537
],
[
537,
40... | [
[
[
"Benzphetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
]
],
[
[
"Benzphetamine",
"{u} (Compound) resembles {v} (Compound)",
"Diphenylpyraline"
],
[
"Diphenylpyraline",
"{u}... | Benzphetamine (Compound) resembles Diphenylpyraline (Compound) and Diphenylpyraline (Compound) resembles Methdilazine (Compound)
Benzphetamine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine (Compound) resembles Methdilazine (Compound)
Benzphetamine (Compound)... |
DB00254 | DB00460 | 964 | 612 | [
"DDInter598",
"DDInter1929"
] | Doxycycline | Verteporfin | Doxycycline is a broad-spectrum antibiotic synthetically derived from [oxytetracycline]. It is a second-generation tetracycline that was first discovered in 1967. Second-generation tetracyclines exhibit lesser toxicity than first-generation tetracyclines. Doxycycline is used to treat a wide variety of gram-positive and... | Verteporfin, marketed as Visudyne, is a benzoporphyrin derivative. It is used as a photosensitizer in photodynamic therapy to eliminate abnormal blood vessels in wet form macular degeneration. Verteporfin accumulates in these abnormal blood vessels and, when stimulated by nonthermal red light with a wavelength of 693 n... | Moderate | 1 | [
[
[
964,
24,
612
]
],
[
[
964,
24,
663
],
[
663,
63,
612
]
],
[
[
964,
25,
1517
],
[
1517,
63,
612
]
],
[
[
964,
25,
640
],
[
640,
2... | [
[
[
"Doxycycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Verteporfin"
]
],
[
[
"Doxycycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
],
... | Doxycycline may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Verteporfin
Doxycycline may lead to a major life threatening interaction when taken with Isotretinoin and Isotretinoin... |
DB00621 | DB01285 | 1,026 | 708 | [
"DDInter1357",
"DDInter445"
] | Oxandrolone | Corticotropin | A synthetic hormone with anabolic and androgenic properties. | Corticotropin (ACTH or adrenocorticotropic hormone) is a polypeptide hormone produced and secreted by the pituitary gland. It is an important player in the hypothalamic-pituitary-adrenal axis. | Moderate | 1 | [
[
[
1026,
24,
708
]
],
[
[
1026,
63,
245
],
[
245,
24,
708
]
],
[
[
1026,
25,
126
],
[
126,
24,
708
]
],
[
[
1026,
40,
443
],
[
443,
... | [
[
[
"Oxandrolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Corticotropin"
]
],
[
[
"Oxandrolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
... | Oxandrolone may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin
Oxandrolone may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cau... |
DB00220 | DB12141 | 798 | 971 | [
"DDInter1276",
"DDInter817"
] | Nelfinavir | Gilteritinib | Nelfinavir is a potent HIV-1 protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children. Nelfinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles. | Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression... | Major | 2 | [
[
[
798,
25,
971
]
],
[
[
798,
25,
1135
],
[
1135,
23,
971
]
],
[
[
798,
24,
466
],
[
466,
62,
971
]
],
[
[
798,
25,
1181
],
[
1181,
... | [
[
[
"Nelfinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gilteritinib"
]
],
[
[
"Nelfinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} m... | Nelfinavir may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Nelfinavir may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may caus... |
DB01100 | DB11978 | 1,568 | 124 | [
"DDInter1470",
"DDInter822"
] | Pimozide | Glasdegib | A diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to haloperidol for the suppression of vocal and motor tics in patients with Tourette syndrome. Although the precise mechanism of action is unknown, blockade of postsynaptic dopamine receptors has been postulated. (From AMA Drug ... | Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionalit... | Major | 2 | [
[
[
1568,
25,
124
]
],
[
[
1568,
62,
112
],
[
112,
23,
124
]
],
[
[
1568,
64,
475
],
[
475,
24,
124
]
],
[
[
1568,
63,
688
],
[
688,
... | [
[
[
"Pimozide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Glasdegib"
]
],
[
[
"Pimozide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole"... | Pimozide may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Glasdegib
Pimozide may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moder... |
DB00261 | DB00991 | 702 | 97 | [
"DDInter93",
"DDInter1358"
] | Anagrelide | Oxaprozin | Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythe... | Oxaprozin is a non-narcotic, non-steroidal anti-inflammatory drug (NSAID), used to relieve the inflammation, swelling, stiffness, and joint pain associated with osteoarthritis and rheumatoid arthritis. | Moderate | 1 | [
[
[
702,
24,
97
]
],
[
[
702,
24,
1274
],
[
1274,
24,
97
]
],
[
[
702,
25,
576
],
[
576,
1,
97
]
],
[
[
702,
25,
371
],
[
371,
40,
... | [
[
[
"Anagrelide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaprozin"
]
],
[
[
"Anagrelide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurbiprofen"
],
[
... | Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Oxaprozin
Anagrelide may lead to a major life threatening interaction when taken with Methadone and Methadone (Compound... |
DB00682 | DB09043 | 126 | 135 | [
"DDInter1951",
"DDInter36"
] | Warfarin | Albiglutide | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | Albiglutide is a glucagon-like peptide-1 agonist (GLP-1) biologic drug indicated in the treatment of type 2 diabetes. It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline). It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. Albiglutide was approved on A... | Minor | 0 | [
[
[
126,
23,
135
]
],
[
[
126,
62,
1647
],
[
1647,
23,
135
]
],
[
[
126,
24,
624
],
[
624,
24,
135
]
],
[
[
126,
62,
323
],
[
323,
2... | [
[
[
"Warfarin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Albiglutide"
]
],
[
[
"Warfarin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Acarbose"
],
[
"Acar... | Warfarin may cause a minor interaction that can limit clinical effects when taken with Acarbose and Acarbose may cause a minor interaction that can limit clinical effects when taken with Albiglutide
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Liotrix and Liotrix may cause a ... |
DB00467 | DB00553 | 1,467 | 92 | [
"DDInter644",
"DDInter1177"
] | Enoxacin | Methoxsalen | A broad-spectrum 6-fluoronaphthyridinone antibacterial agent (fluoroquinolones) structurally related to nalidixic acid. | A naturally occurring furocoumarin compound found in several species of plants, including Psoralea corylifolia. It is a photoactive substance that forms DNA adducts in the presence of ultraviolet A irradiation. | Moderate | 1 | [
[
[
1467,
24,
92
]
],
[
[
1467,
6,
7950
],
[
7950,
45,
92
]
],
[
[
1467,
40,
739
],
[
739,
63,
92
]
],
[
[
1467,
25,
187
],
[
187,
6... | [
[
[
"Enoxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methoxsalen"
]
],
[
[
"Enoxacin",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
... | Enoxacin (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Methoxsalen (Compound)
Enoxacin (Compound) resembles Lomefloxacin (Compound) and Lomefloxacin may cause a moderate interaction that could exacerbate diseases when taken with Methoxsalen
Enoxacin may lead to a major life threatening interaction when t... |
DB00092 | DB00593 | 58 | 1,464 | [
"DDInter40",
"DDInter695"
] | Alefacept | Ethosuximide | Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD. | An anticonvulsant especially useful in the treatment of absence seizures unaccompanied by other types of seizures. | Moderate | 1 | [
[
[
58,
24,
1464
]
],
[
[
58,
63,
1184
],
[
1184,
24,
1464
]
],
[
[
58,
24,
1303
],
[
1303,
63,
1464
]
],
[
[
58,
24,
1101
],
[
1101,
... | [
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ethosuximide"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anakinra"
],
[
... | Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Ethosuximide
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Guselkumab and Guselkumab... |
DB06290 | DB11967 | 1,449 | 710 | [
"DDInter1673",
"DDInter210"
] | Simeprevir | Binimetinib | Simeprevir is a hepatitis C virus (HCV) NS3/4A protease inhibitor indicated in patient's with HCV genotype 1 for the treatment of chronic hepatitis C virus (HCV) infection. HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, an... | Binimetinib, also known as _Mektovi_, is a potent and selective oral mitogen-activated protein kinase 1/2 (MEK 1/2) inhibitor which is combined with [Encorafenib].[A34275,L3335] On June 27, 2018, the Food and Drug Administration approved the combination of [Encorafenib] and binimetinib (BRAFTOVI and MEKTOVI, from Array... | Moderate | 1 | [
[
[
1449,
24,
710
]
],
[
[
1449,
25,
129
],
[
129,
24,
710
]
],
[
[
1449,
24,
466
],
[
466,
63,
710
]
],
[
[
1449,
64,
1220
],
[
1220,
... | [
[
[
"Simeprevir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Binimetinib"
]
],
[
[
"Simeprevir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
],
[
"Enzalut... | Simeprevir may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Simeprevir may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide m... |
DB00444 | DB11730 | 63 | 351 | [
"DDInter1765",
"DDInter1588"
] | Teniposide | Ribociclib | Teniposide is a semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Teniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent cells ... | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | Moderate | 1 | [
[
[
63,
24,
351
]
],
[
[
63,
24,
112
],
[
112,
23,
351
]
],
[
[
63,
24,
283
],
[
283,
62,
351
]
],
[
[
63,
24,
310
],
[
310,
24,
... | [
[
[
"Teniposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
]
],
[
[
"Teniposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[... | Teniposide may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Teniposide may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fe... |
DB00245 | DB01075 | 357 | 1,376 | [
"DDInter181",
"DDInter569"
] | Benzatropine | Diphenhydramine | Benztropine, with the chemical formula 3alpha-diphenylmethoxytropane, is a tropane-based dopamine inhibitor used for the symptomatic treatment of Parkinson's disease. It is a combination molecule between a tropane ring, similar to cocaine, and a diphenyl ether from the dialkylpiperazines determined to be a dopamine upt... | Diphenhydramine - perhaps known most commonly as its brand name formulation Benadryl - is a first-generation H1 receptor antihistamine that is used extensively for the treatment of seasonal allergies, insect bites and stings, and rashes [L5263, L5266, L5269, F3379]. However, it also has antiemetic, antitussive, hypnoti... | Moderate | 1 | [
[
[
357,
24,
1376
]
],
[
[
357,
24,
649
],
[
649,
63,
1376
]
],
[
[
357,
40,
11314
],
[
11314,
1,
1376
]
],
[
[
357,
40,
11234
],
[
11234,... | [
[
[
"Benzatropine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
]
],
[
[
"Benzatropine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
],... | Benzatropine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine
Benzatropine (Compound) resembles Eprazinone (Compound) and Eprazinone (Compound) resembles Diphenhydrami... |
DB06168 | DB08904 | 1,531 | 375 | [
"DDInter281",
"DDInter342"
] | Canakinumab | Certolizumab pegol | Canakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/κ isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. B... | Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent compl... | Major | 2 | [
[
[
1531,
25,
375
]
],
[
[
1531,
62,
1461
],
[
1461,
23,
375
]
],
[
[
1531,
23,
1193
],
[
1193,
62,
375
]
],
[
[
1531,
63,
704
],
[
704,
... | [
[
[
"Canakinumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Canakinumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vitamin E"
],
[
"Vit... | Canakinumab may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Certolizumab pegol
Canakinumab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and ... |
DB01364 | DB01452 | 22 | 993 | [
"DDInter650",
"DDInter532"
] | Ephedrine | Diamorphine | Ephedrine was first described in western literature in 1888, as a naturally occurring component of the ephedra plant, along with [pseudoephedrine]. Ephedrine acts as both a direct and indirect sympathomimetic. It is an alpha- and beta-adrenergic receptor agonist; however, it also causes the indirect release of norepine... | Diamorphine (heroin) is a narcotic analgesic that may be habit-forming. It is a controlled substance (opium derivative) listed in the U.S. Code of Federal Regulations, Title 21 Parts 329.1, 1308.11 (1987). Sale is forbidden in the United States by Federal statute. (Merck Index, 11th ed) Internationally, diamorphine is ... | Minor | 0 | [
[
[
22,
23,
993
]
],
[
[
22,
62,
475
],
[
475,
25,
993
]
],
[
[
22,
24,
1662
],
[
1662,
63,
993
]
],
[
[
22,
63,
1645
],
[
1645,
24,... | [
[
[
"Ephedrine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Diamorphine"
]
],
[
[
"Ephedrine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Morphine"
],
[
"Mo... | Ephedrine may cause a minor interaction that can limit clinical effects when taken with Morphine and Morphine may lead to a major life threatening interaction when taken with Diamorphine
Ephedrine may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid and Picosulfuric acid may... |
DB00214 | DB00758 | 1,028 | 1,347 | [
"DDInter1836",
"DDInter413"
] | Torasemide | Clopidogrel | Torasemide is a high-ceiling loop diuretic. Structurally, it is a pyridine-sulfonylurea used as an antihypertensive agent. Torasemide was first approved for clinical use by the FDA in 1993. | Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke.[A180508,L7213] Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recen... | Minor | 0 | [
[
[
1028,
23,
1347
]
],
[
[
1028,
6,
3486
],
[
3486,
45,
1347
]
],
[
[
1028,
18,
2976
],
[
2976,
57,
1347
]
],
[
[
1028,
21,
28998
],
[
28... | [
[
[
"Torasemide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clopidogrel"
]
],
[
[
"Torasemide",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (Compound)",
... | Torasemide (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Clopidogrel (Compound)
Torasemide (Compound) downregulates STUB1 (Gene) and STUB1 (Gene) is downregulated by Clopidogrel (Compound)
Torasemide (Compound) causes Blood uric acid increased (Side Effect) and Blood uric acid increased (Side Effect) is ... |
DB00620 | DB00945 | 175 | 1,479 | [
"DDInter1855",
"DDInter20"
] | Triamcinolone | Acetylsalicylic acid | Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis. Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain, or first line as a topical treatment of corticosteroid responsive dermat... | Also known as _Aspirin_, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial... | Moderate | 1 | [
[
[
175,
24,
1479
]
],
[
[
175,
24,
1338
],
[
1338,
24,
1479
]
],
[
[
175,
7,
2900
],
[
2900,
45,
1479
]
],
[
[
175,
6,
7720
],
[
7720,
... | [
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic acid"
]
],
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meclofenami... | Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Meclofenamic acid and Meclofenamic acid may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid
Triamcinolone (Compound) upregulates NFKBIA (Gene) and NFKBIA (Gene) is bound by Acet... |
DB08864 | DB11986 | 786 | 484 | [
"DDInter1595",
"DDInter648"
] | Rilpivirine | Entrectinib | Rilpivirine is non-nucleoside reverse transcriptase inhibitor (NNRTI) which is used for the treatment of HIV-1 infections in treatment-naive patients. It is a diarylpyrimidine derivative. The internal conformational flexibility of rilpivirine and the plasticity of it interacting binding site gives it a very high potenc... | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positi... | Moderate | 1 | [
[
[
786,
24,
484
]
],
[
[
786,
62,
112
],
[
112,
23,
484
]
],
[
[
786,
63,
774
],
[
774,
24,
484
]
],
[
[
786,
24,
1320
],
[
1320,
2... | [
[
[
"Rilpivirine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Rilpivirine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Rilpivirine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Entrectinib
Rilpivirine may cause a moderate interaction that could exacerbate diseases when taken with Degarelix and De... |
DB00454 | DB08816 | 1,349 | 578 | [
"DDInter1150",
"DDInter1802"
] | Meperidine | Ticagrelor | A narcotic analgesic that can be used for the relief of most types of moderate to severe pain, including postoperative pain and the pain of labor. Prolonged use may lead to dependence of the morphine type; withdrawal symptoms appear more rapidly than with morphine and are of shorter duration. | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagre... | Moderate | 1 | [
[
[
1349,
24,
578
]
],
[
[
1349,
6,
8374
],
[
8374,
45,
578
]
],
[
[
1349,
21,
28762
],
[
28762,
60,
578
]
],
[
[
1349,
25,
1039
],
[
1039... | [
[
[
"Meperidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
]
],
[
[
"Meperidine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",... | Meperidine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ticagrelor (Compound)
Meperidine (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Ticagrelor (Compound)
Meperidine may lead to a major life threatening interaction when taken with Dexfenfluramine and Dexfenfluramine ... |
DB06616 | DB11652 | 594 | 1,155 | [
"DDInter224",
"DDInter1891"
] | Bosutinib | Tucatinib | Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q... | Tucatinib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer. It was developed by Seattle Genetics and approved by the FDA on April 17, 2020. Tucatinib is a promising new treatment for patients with metastatic breast cancer w... | Major | 2 | [
[
[
594,
25,
1155
]
],
[
[
594,
63,
1101
],
[
1101,
23,
1155
]
],
[
[
594,
63,
1424
],
[
1424,
24,
1155
]
],
[
[
594,
24,
659
],
[
659,
... | [
[
[
"Bosutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tucatinib"
]
],
[
[
"Bosutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
... | Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Tucatinib
Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Quinine and Quinine may ca... |
DB00496 | DB00549 | 194 | 522 | [
"DDInter480",
"DDInter1955"
] | Darifenacin | Zafirlukast | Darifenacin (Enablex®, Novartis) is a medication used to treat urinary incontinence. Darifenacin blocks M3 muscarinic acetylcholine receptors, which mediate bladder muscle contractions. This block reduces the urgency to urinate and so it should not be used in people with urinary retention. It is unknown if M3 receptor ... | Zafirlukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma, often used in conjunction with an inhaled steroid and/or long-acting bronchodilator. It is available as a tablet and is usually dosed twice daily. Another leukotriene receptor antagonist is montelukast (Singulair), wh... | Moderate | 1 | [
[
[
194,
24,
522
]
],
[
[
194,
6,
8374
],
[
8374,
45,
522
]
],
[
[
194,
21,
29226
],
[
29226,
60,
522
]
],
[
[
194,
24,
1487
],
[
1487,
... | [
[
[
"Darifenacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zafirlukast"
]
],
[
[
"Darifenacin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound... | Darifenacin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Zafirlukast (Compound)
Darifenacin (Compound) causes Sinusitis (Side Effect) and Sinusitis (Side Effect) is caused by Zafirlukast (Compound)
Darifenacin may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroq... |
DB01174 | DB12267 | 697 | 1,476 | [
"DDInter1442",
"DDInter233"
] | Phenobarbital | Brigatinib | A barbituric acid derivative that acts as a nonselective central nervous system depressant. It promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations. | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Major | 2 | [
[
[
697,
25,
1476
]
],
[
[
697,
25,
1135
],
[
1135,
23,
1476
]
],
[
[
697,
64,
168
],
[
168,
23,
1476
]
],
[
[
697,
64,
629
],
[
629,
... | [
[
[
"Phenobarbital",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brigatinib"
]
],
[
[
"Phenobarbital",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{... | Phenobarbital may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Phenobarbital may lead to a major life threatening interaction when taken with Bortezomib and Bortezomib may cause a minor inter... |
DB01088 | DB15035 | 714 | 503 | [
"DDInter908",
"DDInter1959"
] | Iloprost | Zanubrutinib | Iloprost is a mimetic of prostacyclin (PGI2; epoprostenol). Iloprost consists of a mixture of the 4R and 4S diastereoisomers at a ratio of approximately 53:47. It is a potent vasodilator with reported anti-thrombotic properties. | Zanubrutinib is a novel Bruton's tyrosine kinase (BTK) inhibitor used for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Mantle cell lymphoma is an aggressive mature B-cell non-Hodgkin lymphoma associated with early relapse, poor clinical outcomes, and long... | Major | 2 | [
[
[
714,
25,
503
]
],
[
[
714,
24,
222
],
[
222,
24,
503
]
],
[
[
714,
63,
121
],
[
121,
24,
503
]
],
[
[
714,
25,
39
],
[
39,
25,
... | [
[
[
"Iloprost",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zanubrutinib"
]
],
[
[
"Iloprost",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutramine... | Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Zanubrutinib
Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Fenfluramine and Fenf... |
DB00486 | DB00690 | 1,614 | 1,216 | [
"DDInter1253",
"DDInter762"
] | Nabilone | Flurazepam | Nabilone (marketed as Cesamet) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). Although structurally distinct from THC, nabilone mimics THC's structure and pharmacological activity through weak partial agonist activity at Cannabinoid-1 (CB1R) and... | A benzodiazepine derivative used mainly as a hypnotic. | Moderate | 1 | [
[
[
1614,
24,
1216
]
],
[
[
1614,
24,
1418
],
[
1418,
1,
1216
]
],
[
[
1614,
24,
481
],
[
481,
40,
1216
]
],
[
[
1614,
63,
216
],
[
216,
... | [
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurazepam"
]
],
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Estazolam"
],
[
"... | Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Estazolam and Estazolam (Compound) resembles Flurazepam (Compound)
Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Quazepam and Quazepam (Compound) resembles Flurazepam (Compound)
Nabilone m... |
DB00790 | DB01075 | 664 | 1,376 | [
"DDInter1431",
"DDInter569"
] | Perindopril | Diphenhydramine | Perindopril is a nonsulfhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is rapidly metabolized in the liver to perindoprilat, its active metabolite, following oral administration. Perindoprilat is a potent, competitive inhibitor of ACE, the enzyme responsible fo... | Diphenhydramine - perhaps known most commonly as its brand name formulation Benadryl - is a first-generation H1 receptor antihistamine that is used extensively for the treatment of seasonal allergies, insect bites and stings, and rashes [L5263, L5266, L5269, F3379]. However, it also has antiemetic, antitussive, hypnoti... | Moderate | 1 | [
[
[
664,
24,
1376
]
],
[
[
664,
24,
401
],
[
401,
24,
1376
]
],
[
[
664,
21,
28921
],
[
28921,
60,
1376
]
],
[
[
664,
63,
530
],
[
530,
... | [
[
[
"Perindopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
]
],
[
[
"Perindopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],... | Perindopril may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine
Perindopril (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Diphenh... |
DB00842 | DB01181 | 686 | 1,532 | [
"DDInter1359",
"DDInter906"
] | Oxazepam | Ifosfamide | Oxazepam is an intermediate-acting, 3-hydroxybenzodiazepine used in the treatment of alcohol withdrawal and anxiety disorders. Oxazepam, like related 3-hydroxybenzodiazepine [lorazepam], is considered less susceptible to pharmacokinetic variability based on patient-specific factors (e.g. age, liver disease) - this feat... | Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent. | Moderate | 1 | [
[
[
686,
24,
1532
]
],
[
[
686,
6,
7524
],
[
7524,
45,
1532
]
],
[
[
686,
21,
28900
],
[
28900,
60,
1532
]
],
[
[
686,
63,
1648
],
[
1648,... | [
[
[
"Oxazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
]
],
[
[
"Oxazepam",
"{u} (Compound) binds {v} (Gene)",
"CYP3A5"
],
[
"CYP3A5",
"{u} (Gene) is bound by {v} (Compound)",
... | Oxazepam (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Ifosfamide (Compound)
Oxazepam (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Ifosfamide (Compound)
Oxazepam may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and... |
DB00280 | DB00804 | 494 | 1,507 | [
"DDInter575",
"DDInter543"
] | Disopyramide | Dicyclomine | A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties. | Dicyclomine is a muscarinic M1, M3, and M2 receptor antagonist as well as a non-competitive inhibitor of histamine and bradykinin used to treat spasms of the intestines seen in functional bowel disorder and irritable bowel syndrome.[A6556,A182555,A234659,L7967] Though it is commonly prescribed, its recommendation may h... | Moderate | 1 | [
[
[
494,
24,
1507
]
],
[
[
494,
6,
2720
],
[
2720,
45,
1507
]
],
[
[
494,
21,
28817
],
[
28817,
60,
1507
]
],
[
[
494,
35,
1594
],
[
1594,... | [
[
[
"Disopyramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dicyclomine"
]
],
[
[
"Disopyramide",
"{u} (Compound) binds {v} (Gene)",
"CHRM3"
],
[
"CHRM3",
"{u} (Gene) is bound by {v} (Compound... | Disopyramide (Compound) binds CHRM3 (Gene) and CHRM3 (Gene) is bound by Dicyclomine (Compound)
Disopyramide (Compound) causes Vision blurred (Side Effect) and Vision blurred (Side Effect) is caused by Dicyclomine (Compound)
Disopyramide (Compound) resembles Doxylamine (Compound) and Disopyramide may cause a moderate in... |
DB00440 | DB01229 | 1,548 | 973 | [
"DDInter1874",
"DDInter1378"
] | Trimethoprim | Paclitaxel (protein-bound) | Trimethoprim is an antifolate antibacterial agent that inhibits bacterial dihydrofolate reductase (DHFR), a critical enzyme that catalyzes the formation of tetrahydrofolic acid (THF) - in doing so, it prevents the synthesis of bacterial DNA and ultimately continued bacterial survival. Trimethoprim is often used in comb... | Paclitaxel can cause developmental toxicity, female reproductive toxicity and male reproductive toxicity according to state or federal government labeling requirements. | Moderate | 1 | [
[
[
1548,
24,
973
]
],
[
[
1548,
6,
8374
],
[
8374,
45,
973
]
],
[
[
1548,
6,
8569
],
[
8569,
57,
973
]
],
[
[
1548,
21,
29501
],
[
29501,... | [
[
[
"Trimethoprim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
]
],
[
[
"Trimethoprim",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compoun... | Trimethoprim may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Trimethoprim (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Paclitaxel (Compound)
Trimethoprim (Compound) binds TYMS (Gene) and TYMS (Gene) is downregulated by Paclitaxel (Compound)
Trimethoprim (Compou... |
DB00881 | DB01075 | 954 | 1,376 | [
"DDInter1554",
"DDInter569"
] | Quinapril | Diphenhydramine | Quinapril is the ethyl ester prodrug of the non-sulfhydryl angiotensin converting enzyme inhibitor quinaprilat.[L8420,L8423] It is used to treat hypertension and heart failure.[L8420,L8423] ACE inhibitors are commonly used as a first line therapy in the treatment of hypertension, along with thiazide diuretics or beta b... | Diphenhydramine - perhaps known most commonly as its brand name formulation Benadryl - is a first-generation H1 receptor antihistamine that is used extensively for the treatment of seasonal allergies, insect bites and stings, and rashes [L5263, L5266, L5269, F3379]. However, it also has antiemetic, antitussive, hypnoti... | Moderate | 1 | [
[
[
954,
24,
1376
]
],
[
[
954,
24,
401
],
[
401,
24,
1376
]
],
[
[
954,
40,
675
],
[
675,
25,
1376
]
],
[
[
954,
21,
28921
],
[
28921,
... | [
[
[
"Quinapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
]
],
[
[
"Quinapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
... | Quinapril may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine
Quinapril (Compound) resembles Dextropropoxyphene (Compound) and Dextropropoxyphene may lead to a major ... |
DB00349 | DB08912 | 902 | 1,040 | [
"DDInter401",
"DDInter462"
] | Clobazam | Dabrafenib | Clobazam belongs to the 1,5-benzodiazepine class of drugs and is marketed under different names, Onfi, Frisium, Urbanyl, and others.. Clobazam was first synthesized in 1966 and first published in 1969, following the incidental synthesis and discovery of the first benzodiazepine chlordiazepoxide in the 1950s. Unlike old... | Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib... | Moderate | 1 | [
[
[
902,
24,
1040
]
],
[
[
902,
6,
4973
],
[
4973,
45,
1040
]
],
[
[
902,
21,
28779
],
[
28779,
60,
1040
]
],
[
[
902,
62,
168
],
[
168,
... | [
[
[
"Clobazam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Clobazam",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Clobazam (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Dabrafenib (Compound)
Clobazam (Compound) causes Dry mouth (Side Effect) and Dry mouth (Side Effect) is caused by Dabrafenib (Compound)
Clobazam may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may... |
DB00907 | DB01232 | 290 | 1,327 | [
"DDInter427",
"DDInter1640"
] | Cocaine (topical) | Saquinavir | Cocaine can cause developmental toxicity and female reproductive toxicity according to an independent committee of scientific and health experts. | Saquinavir is an HIV-1 protease inhibitor used in combination with [ritonavir] and other antiretrovirals for the treatment of human immunodeficiency virus-1 (HIV-1) infection. In 1995 it became the first protease inhibitor approved by the FDA, followed shortly by ritonavir in 1996, and remains in clinical use today due... | Moderate | 1 | [
[
[
290,
24,
1327
]
],
[
[
290,
63,
798
],
[
798,
40,
1327
]
],
[
[
290,
6,
21998
],
[
21998,
45,
1327
]
],
[
[
290,
21,
28741
],
[
28741,... | [
[
[
"Cocaine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saquinavir"
]
],
[
[
"Cocaine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nelfinavir"
],
[
"N... | Cocaine may cause a moderate interaction that could exacerbate diseases when taken with Saquinavir
Cocaine may cause a moderate interaction that could exacerbate diseases when taken with Nelfinavir and Nelfinavir (Compound) resembles Saquinavir (Compound)
Cocaine (Compound) binds CYP3A7-CYP3A51P (Gene) and CYP3A7-CYP3A... |
DB00450 | DB00662 | 78 | 717 | [
"DDInter603",
"DDInter1873"
] | Droperidol | Trimethobenzamide | A butyrophenone with general properties similar to those of haloperidol. It is used in conjunction with an opioid analgesic such as fentanyl to maintain the patient in a calm state of neuroleptanalgesia with indifference to surroundings but still able to cooperate with the surgeon. It is also used as a premedicant, as ... | Trimethobenzamide is a novel antiemetic which prevents nausea and vomiting in humans. Its actions are unclear but most likely involves the chemoreceptor trigger zone (CTZ). In dogs pretreated with trimethobenzamide HCl, the emetic response to apomorphine is inhibited, while little or no protection is afforded against e... | Moderate | 1 | [
[
[
78,
24,
717
]
],
[
[
78,
25,
1425
],
[
1425,
40,
717
]
],
[
[
78,
21,
28921
],
[
28921,
60,
717
]
],
[
[
78,
63,
1594
],
[
1594,
... | [
[
[
"Droperidol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimethobenzamide"
]
],
[
[
"Droperidol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cisapride"
],
[
"Cisa... | Droperidol may lead to a major life threatening interaction when taken with Cisapride and Cisapride (Compound) resembles Trimethobenzamide (Compound)
Droperidol (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Trimethobenzamide (Compound)
Droperidol may cause a moderate interaction tha... |
DB00153 | DB00436 | 1,331 | 323 | [
"DDInter662",
"DDInter179"
] | Ergocalciferol | Bendroflumethiazide | Ergocalciferol is an inactivated vitamin D analog. It is synthesized by some plants in the presence of UVB light. The production of ergocalciferol was prompted by the identification of dietary deficiency, more specifically vitamin D, as the main causative factor for the development of rickets. Ergocalciferol was isolat... | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. It has been used in the treatment of familial hyperkalemia, hypertension, edema, and urinary tract disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p810) | Moderate | 1 | [
[
[
1331,
24,
323
]
],
[
[
1331,
24,
1014
],
[
1014,
1,
323
]
],
[
[
1331,
21,
28972
],
[
28972,
60,
323
]
],
[
[
1331,
24,
720
],
[
720,
... | [
[
[
"Ergocalciferol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bendroflumethiazide"
]
],
[
[
"Ergocalciferol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Benzthiazi... | Ergocalciferol may cause a moderate interaction that could exacerbate diseases when taken with Benzthiazide and Benzthiazide (Compound) resembles Bendroflumethiazide (Compound)
Ergocalciferol (Compound) causes Urine output increased (Side Effect) and Urine output increased (Side Effect) is caused by Bendroflumethiazide... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.